Skip to main content
. 2021 Aug 20;19:247. doi: 10.1186/s12957-021-02363-7

Fig. 3.

Fig. 3

HOXA9 was a direct target of miR-638 in breast cancer. (A) HOXA9 had binding sites with miR-638. (B) Luciferase reporter assay. (C) miR-638 had negative correlation with HOXA9. (D, E) The expression of HOXA9 were observed in MCF-7 cells containing miR-638 mimics or inhibitor **P <0.01